Want to see NGEN full AI Analyst Report?
NGEN Stock Chart & Stats
$4.07
$0.00(0.00%)
At close: 4:00 PM EST
$4.07
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.59 - $6.30
Previous CloseN/A
VolumeN/A
Average Volume (3M)846.57K
Market Cap
$141.37M
Enterprise Value$289.36
Total Cash (Recent Filing)$16.55M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Aug 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding82,193,140
10 Day Avg. Volume933,451
30 Day Avg. Volume846,566
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)159.85
Price to Sales (P/S)0.00
P/FCF Ratio-28.50
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.33Price Target Upside153.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy & FDA AlignmentObjective, multi-domain biomechanical and electrophysiology signals for NVG-291 plus an End-of-Phase 2 FDA alignment materially de-risks the regulatory path. This supports a planned registrational Phase 3 mid-2026 and strengthens the long-term case for a first-in-class pharmacologic approach in chronic SCI.
Low Financial LeverageMinimal debt reduces bankruptcy and interest-rate exposure, preserving strategic flexibility for R&D and partnerships. For a clinical-stage biotech with long development timelines, low leverage is a durable strength that improves survival odds through multi-year trials and potential asset- or collaborator-based financing options.
Demonstrated Capital Markets AccessA successful $60M underwritten offering with institutional bookrunners evidences tangible market support and extends development runway. Sustained access to equity markets and the Nasdaq listing are durable enablers for funding registrational trials and strategic investments until product revenues emerge.
Bears Say
Pre-revenue, Widening LossesThe company remains pre-revenue with materially widening net losses driven by increased R&D and operating spend. Long-term value depends on trial success; persistent losses erode equity, limit internal funding options, and make the business structurally dependent on external capital until commercialization is achieved.
High Cash Burn And Lower Cash BalanceSignificant, rising operating cash outflows and a reduced cash balance create a durable liquidity constraint for expensive registrational trials. Even with recent financings, continued negative free cash flow implies repeated capital raises or strategic partnerships will be needed before revenues, raising execution and timing risk.
Reliance On Equity Financing / Dilution RiskFrequent use of equity instruments (underwritten offering and ATM capacity) signals structural dependence on share issuance to fund operations. This durable financing model increases dilution risk for existing holders and links the company's ability to execute its development plan to capital market conditions rather than internal cash generation.
NervGen Pharma News
NGEN FAQ
What was Nervgen Pharma Corp’s price range in the past 12 months?
Nervgen Pharma Corp lowest stock price was $1.59 and its highest was $6.30 in the past 12 months.
What is Nervgen Pharma Corp’s market cap?
Nervgen Pharma Corp’s market cap is $141.37M.
When is Nervgen Pharma Corp’s upcoming earnings report date?
Nervgen Pharma Corp’s upcoming earnings report date is Aug 12, 2026 which is in 19 days.
How were Nervgen Pharma Corp’s earnings last quarter?
Currently, no data Available
Is Nervgen Pharma Corp overvalued?
According to Wall Street analysts Nervgen Pharma Corp’s price is currently Undervalued.
Does Nervgen Pharma Corp pay dividends?
Nervgen Pharma Corp does not currently pay dividends.
What is Nervgen Pharma Corp’s EPS estimate?
Nervgen Pharma Corp’s EPS estimate is -0.06.
How many shares outstanding does Nervgen Pharma Corp have?
Nervgen Pharma Corp has 82,193,140 shares outstanding.
What happened to Nervgen Pharma Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nervgen Pharma Corp?
Currently, no hedge funds are holding shares in NGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NervGen Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (153.89% Upside)
$10.33 (153.89% Upside)
Blogger Sentiment
Bullish
NGEN Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.3%
Last 30 Days ▲ 40.9%
Last 30 Days ▲ 40.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.21%
Trailing 12-Months
Company Description
Nervgen Pharma Corp
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
NGEN Stock 12 Month Forecast
Average Price Target
$10.33
▲(153.89% Upside)
Technical Analysis
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―
Ownership Overview
20.39% Insiders
0.35% Other Institutional Investors
79.26% Public Companies and
Individual Investors